RVMD
Bearish signalScored 2026-10-11 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Revolution Medicines, Inc.
- Nom
- Revolution Medicines, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $40.1B
- Employés
- 883
- PDG
- Mark A. Goldsmith
- Site web
- https://www.revmed.com
- Marché
- BDTXELVNERASGLUEIDYANRIX
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 104 131 titres (~21 252 374,75 $ US)
- Insiders
- ANDERSON ELIZABETH MGOLDSMITH MARK A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$10,220,691
Avg sell (VWAP, 90d window) $201.66 vs last close $177.96 (-11.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$10,220,691 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-22
- Liquidity
- Liquid $395,661,547/day · 20d vol
- Last synced
-
2026-10-18 09:40:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | Sell · S · 10b5-1 | 301 | $204.72 | $61,621 | Form 4 |
| 2026-09-25 | Cislini Jeff | Sell · S · 10b5-1 | 765 | $207.32 | $158,600 | Form 4 |
| 2026-09-25 | Mancini Anthony | Sell · S · 10b5-1 | 3,121 | $200.54 | $625,885 | Form 4 |
| 2026-09-24 | Mancini Anthony | Sell · S · 10b5-1 | 587 | $200.00 | $117,400 | Form 4 |
| 2026-09-22 | ANDERSON ELIZABETH M | Sell · S · 10b5-1 | 100 | $195.15 | $19,515 | Form 4 |
| 2026-09-18 | Mancini Anthony | Sell · S · 10b5-1 | 1,764 | $196.94 | $347,402 | Form 4 |
| 2026-09-16 | Anders Jack | Sell · S · 10b5-1 | 3,992 | $199.30 | $795,618 | Form 4 |
| 2026-09-16 | Cislini Jeff | Sell · S · 10b5-1 | 3,314 | $199.30 | $660,491 | Form 4 |
| 2026-09-16 | GOLDSMITH MARK A | Sell · S · 10b5-1 | 13,775 | $199.30 | $2,745,402 | Form 4 |
| 2026-09-16 | Horn Margaret A | Sell · S · 10b5-1 | 4,891 | $199.30 | $974,792 | Form 4 |
| 2026-09-16 | Kelsey Stephen Michael | Sell · S · 10b5-1 | 5,484 | $199.30 | $1,092,979 | Form 4 |
| 2026-09-16 | Mancini Anthony | Sell · S · 10b5-1 | 1,747 | $199.30 | $348,183 | Form 4 |
| 2026-09-16 | Sandler Alan B. | Sell · S · 10b5-1 | 336 | $199.30 | $66,966 | Form 4 |
| 2026-09-11 | Kelsey Stephen Michael | Sell · S · 10b5-1 | 3,270 | $205.81 | $672,991 | Form 4 |
| 2026-09-10 | Mancini Anthony | Sell · S · 10b5-1 | 300 | $207.17 | $62,152 | Form 4 |
| 2026-08-21 | Cislini Jeff | Sell · S · 10b5-1 | 3,314 | $212.06 | $702,761 | Form 4 |
| 2026-08-21 | GOLDSMITH MARK A | Sell · S · 10b5-1 | 3,621 | $212.08 | $767,933 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-11 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
RVMD is a pre-revenue biotech with zero revenue, persistent cash burn, and no near-term path to profitability, making its weak fundamental trajectory (score: 25) a critical concern despite adequate liquidity (score: 85).
The first sentence of the analysis written for RVMD on 2026-10-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $9.3M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $9.3M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 7.14 · operating margin 0.0%
Suggested stop 136.77, nearest stored support minus 0.5 ATR(23.1% under the last close). Reward/risk to the next stored resistance is 1.13. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | -3796.1% | -704.1% | -636.5% | |
| Ebitda Margin | 0.0% | 0.0% | -3715.7% | -676.8% | -611.6% | |
| Operating Profit Margin | 0.0% | 0.0% | -4207.1% | -730.0% | -639.7% | |
| Pretax Profit Margin | 0.0% | 0.0% | -3798.7% | -704.1% | -636.6% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Net Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Current Ratio | 7.145 | 14.200 | 13.064 | 10.651 | 9.773 | |
| Quick Ratio | 7.145 | 14.200 | 13.064 | 10.651 | 9.773 | |
| Solvency Ratio | -1.541 | -2.007 | -1.813 | -1.886 | -1.327 | |
| Cash Ratio | 1.321 | 3.313 | 4.839 | 2.604 | 1.798 | |
| Price To Earnings Ratio | -13.387 | -12.218 | -7.430 | -7.734 | -10.190 | |
| Price To Earnings Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Forward Price To Earnings Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Price To Earnings Diluted Ratio | -13.387 | -12.218 | -7.430 | -7.734 | -10.190 | |
| Price To Earnings Diluted Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Price To Book Ratio | 9.283 | 3.239 | 1.777 | 2.803 | 3.041 | |
| Price To Sales Ratio | 0.000 | 0.000 | 280.236 | 54.283 | 62.352 | |
| Price To Free Cash Flow Ratio | -16.574 | -12.923 | -9.057 | -8.165 | -11.922 | |
| Price To Operating Cash Flow Ratio | -16.869 | -13.162 | -9.257 | -8.558 | -12.451 | |
| Debt To Assets Ratio | 0.067 | 0.053 | 0.043 | 0.079 | 0.090 | |
| Debt To Equity Ratio | 0.097 | 0.060 | 0.048 | 0.094 | 0.111 | |
| Debt To Capital Ratio | 0.089 | 0.057 | 0.046 | 0.086 | 0.100 | |
| Long Term Debt To Capital Ratio | 0.080 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.443 | 1.129 | 1.129 | 1.185 | 1.225 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.010 | 0.063 | 0.063 | |
| Operating Cash Flow Ratio | -3.091 | -3.401 | -2.437 | -3.620 | -2.439 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -30.274 | -6.343 | -5.008 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.018 | 1.018 | 1.022 | 1.048 | 1.044 | |
| Debt Service Coverage Ratio | -45.005 | 0.000 | -1,408.432 | 0.000 | -14,978.917 | |
| Interest Coverage Ratio | -48.796 | 0.000 | -1,607.871 | 0.000 | -15,667.333 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5.657 | -4.104 | -3.986 | -3.495 | -2.209 | |
| Capital Expenditure Coverage Ratio | -56.144 | -54.078 | -45.358 | -20.747 | -22.546 | |
| Dividend Paid And Capex Coverage Ratio | -56.144 | -54.078 | -45.358 | -20.747 | -22.546 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.680 | -11.765 | -6.128 | -7.614 | -9.962 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-60.0% |
| Ebit Margin | 0.0% | 0.0% | ▲1027.4% |
| Ebitda Margin | 0.0% | 0.0% | ▲1000.8% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1115.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲1027.9% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Net Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Current Ratio | 7.145 | ▼-7.056 | ▼-3.822 |
| Quick Ratio | 7.145 | ▼-7.056 | ▼-3.822 |
| Solvency Ratio | -1.541 | ▲0.466 | ▲0.174 |
| Cash Ratio | 1.321 | ▼-1.992 | ▼-1.454 |
| Price To Earnings Ratio | -13.387 | ▼-1.169 | ▼-3.195 |
| Price To Earnings Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Forward Price To Earnings Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Price To Earnings Diluted Ratio | -13.387 | ▼-1.169 | ▼-3.195 |
| Price To Earnings Diluted Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Price To Book Ratio | 9.283 | ▲6.044 | ▲5.255 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-79.374 |
| Price To Free Cash Flow Ratio | -16.574 | ▼-3.651 | ▼-4.846 |
| Price To Operating Cash Flow Ratio | -16.869 | ▼-3.707 | ▼-4.809 |
| Debt To Assets Ratio | 0.067 | ▲0.014 | ▲0.001 |
| Debt To Equity Ratio | 0.097 | ▲0.037 | ▲0.015 |
| Debt To Capital Ratio | 0.089 | ▲0.032 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.080 | ▲0.080 | ▲0.064 |
| Financial Leverage Ratio | 1.443 | ▲0.314 | ▲0.221 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.027 |
| Operating Cash Flow Ratio | -3.091 | ▲0.310 | ▼-0.093 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲8.325 |
| Free Cash Flow Operating Cash Flow Ratio | 1.018 | ▼-0.001 | ▼-0.012 |
| Debt Service Coverage Ratio | -45.005 | ▼-45.005 | ▲3241.466 |
| Interest Coverage Ratio | -48.796 | ▼-48.796 | ▲3416.004 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -5.657 | ▼-1.553 | ▼-1.767 |
| Capital Expenditure Coverage Ratio | -56.144 | ▼-2.066 | ▼-16.369 |
| Dividend Paid And Capex Coverage Ratio | -56.144 | ▼-2.066 | ▼-16.369 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.681 | ▼-1.916 | ▼-3.851 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $15.14B | $7.34B | $3.25B | $1.92B | $1.83B | |
| Enterprise value | $14.92B | $6.93B | $2.64B | $1.82B | $1.79B | |
| EV / Sales | 0.00x | 0.00x | 227.72x | 51.53x | 60.93x | |
| EV / Op. cash flow | -16.62x | -12.43x | -7.52x | -8.12x | -12.17x | |
| EV / Free cash flow | -16.33x | -12.21x | -7.36x | -7.75x | -11.65x | |
| EV / EBITDA | -13.68x | -11.77x | -6.13x | -7.61x | -9.96x | |
| Net debt / EBITDA | 0.21x | 0.69x | 1.41x | 0.41x | 0.23x | |
| Current ratio | 7.14x | 14.20x | 13.06x | 10.65x | 9.77x | |
| Income quality | 0.79x | 0.93x | 0.80x | 0.90x | 0.79x | |
| Graham net-net | $7 | $12 | $14 | $6 | $6 | |
| Tax burden | 100.0% | 99.9% | 99.2% | 99.8% | 100.0% | |
| Interest burden | 102.2% | 100.0% | 100.1% | 100.0% | 100.0% | |
| Working capital | $1.78B | $2.16B | $1.74B | $598.2M | $529.4M | |
| Invested capital | $2.02B | $2.38B | $1.91B | $745.4M | $675.1M | |
| Return on assets | -48.0% | -23.5% | -21.2% | -30.6% | -25.4% | |
| Operating ROA | -48.1% | -29.8% | -33.9% | -33.3% | -28.8% | |
| Return on tangible assets | -49.5% | -24.1% | -21.9% | -33.7% | -28.2% | |
| Return on equity | -69.3% | -26.5% | -23.9% | -36.3% | -31.0% | |
| Return on invested capital | -56.8% | -28.6% | -25.1% | -34.1% | -27.5% | |
| Return on capital employed | -57.3% | -28.8% | -25.4% | -34.4% | -27.7% | |
| Earnings yield | -7.5% | -8.2% | -13.4% | -12.9% | -10.2% | |
| Free cash flow yield | -6.0% | -7.7% | -11.0% | -12.2% | -8.4% | |
| Capex / Op. cash flow | -1.8% | -1.8% | -2.2% | -4.8% | -4.4% | |
| Capex / Depreciation | -59.3% | 87.2% | 83.0% | 112.0% | 89.0% | |
| Capex / Sales | 0.0% | 0.0% | 66.7% | 30.6% | 22.2% | |
| SG&A / Sales | 0.0% | 0.0% | 653.0% | 114.7% | 103.6% | |
| R&D / Sales | 0.0% | 0.0% | 3654.1% | 715.3% | 636.1% | |
| Stock comp / Sales | 0.0% | 0.0% | 533.4% | 88.2% | 70.5% | |
| Intangibles / Total assets | 3.0% | 2.8% | 3.5% | 9.0% | 10.1% | |
| Days sales outstanding | 0d | 0d | 40d | 48d | 74d | |
| Days payables outstanding | 1424d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 40d | 48d | 74d | |
| Cash conversion cycle | -1424d | 0d | 40d | 48d | 74d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-26 Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Elizabeth Anderson sold 10,143 shares of the firm''s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the transaction, the director directly owned 4,333 shares
- 2026-09-24 Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
- 2026-09-20 Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Alan Sandler sold 341 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $67,940.84. Following the completion of the transaction, the insider directly owned 52,868 shares of the
- 2026-09-20 Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 4,053 shares of the company''s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the transaction, the chief financial officer owned 119,216
- 2026-09-18 Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.
- 2026-09-18 Engineers Gate Manager LP Buys 4,356 Shares of Revolution Medicines, Inc. $RVMD Engineers Gate Manager LP increased its stake in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 144.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,380 shares of the company''s stock after purchasing an additional 4,356 shares during the quarter.
- 2026-09-17 Stephen Michael Kelsey Sells 92,531 Shares of Revolution Medicines (NASDAQ:RVMD) Stock Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Stephen Kelsey sold 92,531 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the transaction, the insider directly owned 291,876 shares of the company''s stock, valued at
- 2026-09-17 Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company''s new medicine might become the top-prescribed treatment in its indication.
- 2026-09-15 Concurrent Investment Advisors LLC Invests $475,000 in Revolution Medicines, Inc. $RVMD Concurrent Investment Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,534 shares of the company''s stock, valued at approximately $475,000. Several other large investors have also modified their
- 2026-09-14 Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company''s RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.